Anna C Calkin

List of Publications by Year
in descending order

59 papers	4,133 citations	185998 28 h-index	143772 57 g-index
67 all docs	67 docs citations	67 times ranked	6627 citing authors

#	Article	IF	Citations
1	Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nature Reviews Molecular Cell Biology, 2012, 13, 213-224.	16.1	616
2	Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes, 2009, 58, 1229-1236.	0.3	468
3	Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes. Diabetes, 2008, 57, 2461-2469.	0.3	376
4	Liver X Receptor Signaling Pathways and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1513-1518.	1.1	257
5	Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein Eâ€“Deficient Mice. Circulation, 2007, 115, 2178-2187.	1.6	233
6	Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux. Circulation, 2009, 120, 2095-2104.	1.6	167
7	FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metabolism, 2021, 33, 1671-1684.e4.	7.2	165
8	Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 295-307.	1.1	147
9	Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products. Journal of the American Society of Nephrology: JASN, 2004, 15, 2125-2138.	3.0	137
10	Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout Mice. Journal of the American Society of Nephrology: JASN, 2005, 16, 363-373.	3.0	121
11	Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1903-1909.	1.1	120
12	PPAR-Î± and -Î³ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrology Dialysis Transplantation, 2006, 21, 2399-2405.	0.4	101
13	An integrative systems genetic analysis of mammalian lipid metabolism. Nature, 2019, 567, 187-193.	13.7	101
14	The IDOLâ€“UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes and Development, 2011, 25, 1262-1274.	2.7	75
15	Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia, 2006, 49, 766-774.	2.9	72
16	Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia, 2011, 54, 681-689.	2.9	61
17	Estrogen Receptor (ER)Î±-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression. Journal of Biological Chemistry, 2015, 290, 5566-5581.	1.6	61
18	The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia, 2008, 51, 1731-1740.	2.9	57

#	Article	IF	Citations
19	FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20107-20112.	3.3	53
20	Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. Journal of Molecular Endocrinology, 2017, 58, R225-R240.	1.1	50
21	The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. Journal of Clinical Investigation, 2011, 121, 3062-3071.	3.9	50
22	Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. Nature Metabolism, 2021, 3, 1476-1483.	5.1	43
23	Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis, 2007, 195, 17-22.	0.4	41
24	Compression force sensing regulates integrin Î±IIbÎ²3 adhesive function on diabetic platelets. Nature Communications, 2018, 9, 1087.	5.8	39
25	Rapid Potentiation of Endothelium-Dependent Vasodilation by Estradiol in Postmenopausal Women Is Mediated via Cyclooxygenase 2. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5072-5075.	1.8	38
26	The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. American Journal of Physiology - Renal Physiology, 2010, 299, F528-F535.	1.3	36
27	Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia, 2013, 56, 1155-1165.	2.9	34
28	Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-Î² in a murine diabetic model of atherosclerosis. Diabetologia, 2010, 53, 170-179.	2.9	32
29	Direct antiatherosclerotic effects of PPAR agonists. Current Opinion in Lipidology, 2009, 20, 24-29.	1.2	29
30	The Antioxidant Moiety of MitoQ Imparts Minimal Metabolic Effects in Adipose Tissue of High Fat Fed Mice. Frontiers in Physiology, 2019, 10, 543.	1.3	29
31	Diabetes Mellitus-Associated Atherosclerosis. American Journal of Cardiovascular Drugs, 2006, 6, 15-40.	1.0	26
32	PPAR Agonists and Cardiovascular Disease in Diabetes. PPAR Research, 2008, 2008, 1-12.	1.1	25
33	Thrombosis in diabetes: a shear flow effect?. Clinical Science, 2017, 131, 1245-1260.	1.8	25
34	The clot thickensâ€"oxidized lipids and thrombosis. Nature Medicine, 2007, 13, 1015-1016.	15.2	23
35	Large artery biomechanics and diastolic dysfunctionin patients with Type 2 diabetes. Diabetic Medicine, 2011, 28, 54-60.	1.2	22
36	Transgenic Expression of Dominant-Active IDOL in Liver Causes Diet-Induced Hypercholesterolemia and Atherosclerosis in Mice. Circulation Research, 2014, 115, 442-449.	2.0	21

#	Article	IF	Citations
37	The E3 ligase MARCH5 is a PPARÎ³ target gene that regulates mitochondria and metabolism in adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E293-E304.	1.8	19
38	Genome-Wide Association Studies Identify New Targets in Cardiovascular Disease. Science Translational Medicine, 2010, 2, 48ps46.	5.8	18
39	Deletion of Trim28 in committed adipocytes promotes obesity but preserves glucose tolerance. Nature Communications, 2021, 12, 74.	5.8	16
40	SOD2 in skeletal muscle: New insights from an inducible deletion model. Redox Biology, 2021, 47, 102135.	3.9	14
41	IDOL regulates systemic energy balance through control of neuronal VLDLR expression. Nature Metabolism, 2019, 1, 1089-1100.	5.1	12
42	Loss of the long non-coding RNA OIP5-AS1 exacerbates heart failure in a sex-specific manner. IScience, 2021, 24, 102537.	1.9	12
43	Lack of Strategic Funding and Long-Term Job Security Threaten to Have Profound Effects on Cardiovascular Researcher Retention in Australia. Heart Lung and Circulation, 2020, 29, 1588-1595.	0.2	10
44	Genome-Wide Association Study Identifies a Functional <i>SIDT2</i> Variant Associated With HDL-C (High-Density Lipoprotein Cholesterol) Levels and Premature Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2494-2508.	1.1	10
45	Sex differences in white adipose tissue expansion: emerging molecular mechanisms. Clinical Science, 2021, 135, 2691-2708.	1.8	10
46	Addressing Gender Equity in Senior Leadership Roles in Translational Science. ACS Pharmacology and Translational Science, 2020, 3, 773-779.	2.5	9
47	PPARs and Diabetes-Associated Atherosclerosis. Current Pharmaceutical Design, 2007, 13, 2736-2741.	0.9	8
48	Lipin 1 modulates mRNA splicing during fasting adaptation in liver. JCI Insight, 2021, 6, .	2.3	7
49	A roadmap of strategies to support cardiovascular researchers: from policy to practice. Nature Reviews Cardiology, 2022, 19, 765-777.	6.1	6
50	Tissue-specific expression of Cas9 has no impact on whole-body metabolism in four transgenic mouse lines. Molecular Metabolism, 2021, 53, 101292.	3.0	5
51	Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease. Frontiers in Physiology, 2022, 13, 839471.	1.3	4
52	Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease. Frontiers in Physiology, 2020, 11, 518.	1.3	3
53	The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. Metabolites, 2021, 11, 340.	1.3	3
54	Apolipoprotein A-I for Cardiac Recovery Postâ€"Myocardial Infarction. JACC Basic To Translational Science, 2021, 6, 768-771.	1.9	2

#	Article	IF	Citations
55	Vildagliptin. Drugs, 2006, 66, 2002-2004.	4.9	1
56	The Use of L-sIDOL Transgenic Mice as a Murine Model to Study Hypercholesterolemia and Atherosclerosis. Methods in Molecular Biology, 2017, 1583, 65-72.	0.4	1
57	The CCC Complex COMManDs Control of LDL Cholesterol Levels. Circulation Research, 2018, 122, 1629-1631.	2.0	1
58	Novel regulation of lipid metabolism. Impact, 2017, 2017, 37-39.	0.0	0
59	LACK OF FUNDING AND LONG-TERM JOB SECURITY THREATENS TO HAVE PROFOUND EFFECTS ON CARDIOVASCULAR RESEARCHER RETENTION IN AUSTRALIA. Journal of Hypertension, 2021, 39, e12.	0.3	0